Champions Oncology, Inc. (NASDAQ: CSBR) is a Healthcare company (Biotechnology) with a market capitalization of $64M. The Maz Rating grades it against the other companies in its sector.
Champions Oncology, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $4.59, Champions Oncology, Inc. trades at 1.1x sales and 16.5x book value, with an EV/EBITDA of 158.0. Over the last twelve months it generated about $60M of revenue and a net loss of $1M. It runs a gross margin of 49.3%, an operating margin of -1.7% and a net margin of -1.9%. It shows return on equity of -27.9%, return on invested capital of -6.8% and a free cash flow yield of -9.6%. On the balance sheet: a debt-to-equity ratio of 2.82 and a current ratio of 1.03. Over the past 52 weeks the share price ranged from $4.52 to $8.31, with a beta of 0.45.
Champions Oncology, Inc. does not currently pay a dividend.
7 Wall Street analyst ratings cover the stock: 5 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of July 2026, Champions Oncology, Inc. (CSBR) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 1.27% / 30% · (Cash+Inv) / Mkt Cap (36m) 6.38% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 1.27% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 6.38% / 33% · Receivables / Mkt Cap (36m) 19.9% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 1.27% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 6.38% / 33.33% · Receivables / Mkt Cap (24m) 19.9% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 3.43% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 20.9% / 33.33% · Receivables / Avg Assets (4Q) 42.4% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 2.61% / 33.33% · (Cash+ST Inv) / Total Assets 13.1% / 33.33% · (Cash+Recv) / Total Assets 54.0% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of July 2026, Champions Oncology, Inc. (CSBR) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Champions Oncology, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
Champions Oncology, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated July 31, 2026 (Q1 2027). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.